Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI ≥50 kg/m 2

Autor: Juan Carlo Avalon, Wei Fang, Laura Davisson, Cavan P. O’Kane, Kara Piechowski, Christopher Bianco, Jordan L. Lacoste
Rok vydání: 2021
Předmět:
Zdroj: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 42:112-118
ISSN: 1875-9114
0277-0008
DOI: 10.1002/phar.2651
Popis: BACKGROUND Apixaban and rivaroxaban are increasingly used for thromboembolism prophylaxis in patients with nonvalvular atrial fibrillation (NVAF) and commonly in patients with obesity and body mass index (BMI) ≥50 kg/m2 despite limited data. OBJECTIVES This study aimed to establish the effectiveness and safety of apixaban and rivaroxaban in patients with NVAF and BMI ≥50 kg/m2 . METHODS A single health-system, retrospective cohort study evaluated the effectiveness and safety of apixaban and rivaroxaban initiated in adult patients (≥18 years of age) with BMI ≥50 kg/m2 and NVAF. Outcomes of ischemic stroke, systemic embolic events, and bleeding were compared to a cohort of patients with BMI 18 to 30 kg/m2 . RESULTS After 1,619 patient-years' worth of follow up in 595 patients, the primary endpoint of incidence of ischemic stroke was numerically similar in both groups, 1.3 per 100 patient-years in the BMI ≥50 kg/m2 group, compared to 2.0 per 100 patient-years in the BMI
Databáze: OpenAIRE
Externí odkaz: